AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16381264
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion starting at 2 mg/kg/h reduced to 1 mg/kg/h
Trial: 8904056
Drug: Aspirin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (80 mg daily)
Trial: 26655421
Drug: Ibrutinib (420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib (420 mg daily orally) with bendamustine plus rituximab
Trial: 22992073
Drug: BG-12 (dimethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BG-12 (dimethyl fumarate) 240 mg twice daily
Trial: 22992073
Drug: BG-12 (dimethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BG-12 (dimethyl fumarate) 240 mg three times daily
Trial: 19240689
Drug: NV1FGF plasmid
RxNorm normalized name: plasmin
DrugBank: Fibrinolysin (DB05254)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NV1FGF plasmid DNA (0.5, 2, or 4 mg administered as eight IM injections)
Trial: 10022444
Drug: Human BNP
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human BNP infusion (3.0 pmol/kg min)
Trial: 10022444
Drug: NEP inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEP inhibitor (SCH 42495, 300 mg)
Trial: 10022444
Drug: Combined BNP
RxNorm normalized name: BNP
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined BNP and NEP inhibitor
Trial: 2081639
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated lyophilized Schwartz strain of measles vaccine
Trial: 7002178
Drug: Tofizopam 100
RxNorm normalized name: tofisopam
DrugBank: Tofisopam (DB08811)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Tofizopam 100 mg
Trial: 29970053
Drug: Iron-folic acid
RxNorm normalized name: folic acid / iron carbonyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-folic acid supplements provided by trained BRAC village volunteers during early pregnancy
Trial: 27378790
Drug: Levosimendan (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (0.1 μg/kg/min for 24 h without a loading dose)
Trial: 12728461
Drug: 5 ppm
RxNorm normalized name: silver nitrate 55 PPM TOPICAL GEL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ppm NO via inhalation followed by a recruitment maneuver (RM) with sustained inflation pressure of 30‐35 cmH2O for 30 seconds (Group 1)
Trial: 12728461
Drug: NO inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NO inhalation alone (Group 3)
Trial: 10383502
Drug: OAC regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC regimen (omeprazole 20 mg b.d., amoxycillin 500 mg t.d.s., clarithromycin 200 mg b.d.)
Trial: 10383502
Drug: LAC regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAC regimen (lansoprazole 30 mg b.d., amoxycillin 500 mg t.d.s., clarithromycin 200 mg b.d.)
Trial: 10383502
Drug: RAC regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAC regimen (rabeprazole 20 mg b.d., amoxycillin 500 mg t.d.s., clarithromycin 200 mg b.d.)
Trial: 8848769
Drug: Pasteur vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasteur vaccine (5 micrograms at 0, 1, 2, 6, 18 months)
Trial: 8848769
Drug: Recombinant vaccine
RxNorm normalized name: CHO Cells Recombinant Vaccine
DrugBank: CHO Cells Recombinant Vaccine (DB15893)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant vaccine (40 micrograms at 0, 1, 2, 6, 12 months)
Trial: 8848769
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional doses
Trial: 8848769
Drug: Monitoring and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monitoring and administration of additional doses
Trial: 1906584
Drug: Insulin alone
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin alone (n = 22)
Trial: 1906584
Drug: Combined insulin-glibenclamide
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined insulin-glibenclamide therapy (n = 25)
Trial: 6341191
Drug: Urol medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urol medication
Trial: 6341191
Drug: Spasmoanalgetic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spasmoanalgetic therapy
Trial: 28426542
Drug: Inhalation aromatherapy
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation aromatherapy (3-minute inhalation before chemotherapy cycles)
Trial: 17393787
Drug: Control (routine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (routine treatment only)
Trial: 15848554
Drug: Enteric-coated mycophenolate
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteric-coated mycophenolate sodium (EC-MPS; 720 mg bid)
Trial: 15848554
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF; 1000 mg bid)
Trial: 7616802
Drug: Heparin (1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (1250 IU twice a day subcutaneously for 30 days)
Trial: 7616802
Drug: Prednisone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (10 mg per day for 30 days)
Trial: 28089764
Drug: Tailored online
RxNorm normalized name: FILTER,SUCTION,INLINE #FHBF200S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored online coaching with EHR tracking tools (CC)
Trial: 16879301
Drug: MBP8298 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBP8298 (500 mg administered intravenously every 6 months)
Trial: 31793731
Drug: S. alopecuroides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S. alopecuroides extract (400 mg capsules, once daily)
Trial: 27614318
Drug: Lubricin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubricin (150 μg/mL) eye drops
Trial: 24746942
Drug: Beclometasone/formoterol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclometasone/formoterol (200 μg/24 μg for children; 400 μg/24 μg for adolescents and adults) via pMDI with AeroChamber Plus™
Trial: 24746942
Drug: Beclometasone/formoterol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclometasone/formoterol (400 μg/24 μg) via pMDI with AeroChamber Plus™
Trial: 23688206
Drug: Acoustic Wave
RxNorm normalized name: aconite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acoustic Wave Therapy (AWT(®)), treated once a week for 7 weeks, total of 8 treatments
Trial: 20074465
Drug: 1 percent
RxNorm normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin 0.1 Percent]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 percent chlorhexidine gel (TG)
Trial: 15120931
Drug: Iseganan 9mg
RxNorm normalized name: Iseganan
DrugBank: Iseganan (DB16010)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iseganan 9mg oral rinse, swished/swallowed six times daily for up to 21 days.
Trial: 15120931
Drug: Placebo oral
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral rinse, swished/swallowed six times daily for up to 21 days.
Trial: 9783307
Drug: rHuEpo subcutaneously,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEpo subcutaneously, 900 U/kg week‐1, 3 times weekly, supplemented with iron and vitamin E
Trial: 25113527
Drug: Efavirenz 600
RxNorm normalized name: efavirenz 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz 600 mg nightly for 7 days
Trial: 25113527
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of a serotonin 2A receptor antagonist
Trial: 21366472
Drug: Bolus administration
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus administration of furosemide every 12 hours
Trial: 21366472
Drug: High-dose furosemide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose furosemide (2.5 times previous oral dose)
Trial: 21366472
Drug: Low-dose furosemide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose furosemide (equivalent to previous oral dose)
Trial: 9347277
Drug: Propafenone (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone (450 to 750 mg)
Trial: 7504134
Drug: Doxazosin (10.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (10.3 ± 6.3 mg/day)
Trial: 7504134
Drug: Hydrochlorothiazide (44.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (44.0 ± 11.0 mg/day)
Trial: 30462162
Drug: Combined-exercise program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined-exercise program and nutrition supplement
Trial: 29326030
Drug: ADT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADT plus abiraterone acetate (1000 mg) and prednisone (5 mg) once daily
Trial: 24559816
Drug: Sedative music
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedative music intervention (soft, instrumental slow music, 60-80 beats per minute, 40 minutes duration, for 6 weeks)
Trial: 20568023
Drug: Conivaptan 20
RxNorm normalized name: conivaptan 20 mg/100 mL-D5% intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conivaptan 20 mg IV as a bolus followed by 20 mg IV over 24 h
Trial: 12124866
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral prasterone
Trial: 12124866
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg oral prasterone
Trial: 10574618
Drug: IFN-beta1b (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-beta1b (8 million international units, subcutaneous)
Trial: 10574618
Drug: IFN-beta1a (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-beta1a (6 million international units, intramuscular)
Trial: 1827021
Drug: Isradipine (7.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (7.9 +/- 3.5 mg/day)
Trial: 1827021
Drug: Atenolol (69.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (69.2 +/- 43.5 mg/day)
Trial: 31757691
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injections (IAIs) 2 mg every 4 weeks for the first 6 months, followed by 2 mg every 8 weeks.
Trial: 28255094
Drug: Face-to-face cognitive-behavioural
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face cognitive-behavioural therapy (CBT)
Trial: 26729009
Drug: Concise cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concise cognitive behavioural therapy and/or pharmacotherapy
Trial: 21637131
Drug: MFGM-enriched complementary
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MFGM-enriched complementary food (40 g/day)
Trial: 12505243
Drug: Experimental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatment after disease progression or relapse
Trial: 9860474
Drug: Adjuvant hepatic
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant hepatic arterial infusion (HAI) of 5-fluorouracil (5-FU) 1000 mg/m2 per day for 5 days plus folinic acid 200 mg/m2 per day for 5 days
Trial: 9860474
Drug: Adjuvant hepatic
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant hepatic arterial infusion (HAI) of 5-FU
Trial: 2375249
Drug: Tolfenamic acid
RxNorm normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolfenamic acid 200 mg
Trial: 2375249
Drug: Tolfenamic acid
RxNorm normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolfenamic acid 400 mg
Trial: 29611892
Drug: MLC901 (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLC901 (0.8 g capsules 3 times daily)
Trial: 25272643
Drug: Stannous chloride
RxNorm normalized name: Stannous chloride
DrugBank: Stannous chloride (DB11056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stannous chloride dihydrate at concentrations of 200, 400, 600, and 800 microg, followed by intravenous administration of 99mTc at 30 min intervals in group one.
Trial: 25272643
Drug: Constant concentration
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant concentration of 400 microg of Sn PYP, followed by administration of 99mTc at different time intervals (15, 30, 60, and 120 min) in group two.
Trial: 18235411
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of thoracic irradiation and chemotherapy (platinum salts and etoposide)
Trial: 7569587
Drug: HRT (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT (oral or non-oral 17-beta estradiol at skeletally protective dose)
Trial: 2161302
Drug: Itraconazole (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (100 mg once daily) for 30 days in dermatophytosis
Trial: 2161302
Drug: Itraconazole (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (100 mg once daily) for 15 days in pityriasis versicolor
Trial: 2161302
Drug: Open phase
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open phase treatment with itraconazole (100 mg once daily) for 15 days
Trial: 505491
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (1 gram every 4 hours up to 21 days)
Trial: 31400046
Drug: Low-dose meloxicam
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose meloxicam (0.025 mg/kg/day PO)
Trial: 29211013
Drug: Cenerimod 1
RxNorm normalized name: Cenerimod
DrugBank: Cenerimod (DB12705)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenerimod 1 mg
Trial: 29211013
Drug: Cenerimod 0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenerimod 0.5, 1, 2, or 4 mg (once daily for 35 days)
Trial: 29211013
Drug: Cenerimod 25
RxNorm normalized name: Cenerimod
DrugBank: Cenerimod (DB12705)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenerimod 25 mg
Trial: 29211013
Drug: Cenerimod >1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenerimod >1 mg
Trial: 29211013
Drug: Cenerimod ≥10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenerimod ≥10 mg
Trial: 25510210
Drug: High-dosage betahistine
RxNorm normalized name: betahistine
DrugBank: Betahistine (DB06698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dosage betahistine (144mg/day)
Trial: 23448592
Drug: 10 doses
RxNorm normalized name: diazepam
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 doses of mupirocin (twice daily for 5 days)
Trial: 23448592
Drug: 6 doses
RxNorm normalized name: interferon alfa-2b,recomb. 3 million unit/0.2 mL (6 doses per pen = 18 million unit) SUBCUT PEN INJECTOR KIT (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 doses of mupirocin (twice daily for 3 days or thrice daily for 2 days)
Trial: 21702402
Drug: Pilocarpine 5
RxNorm normalized name: PILOCARPINE 5MG/UNT OPH,CRC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilocarpine 5 mg twice daily
Trial: 21702402
Drug: Pilocarpine 5
RxNorm normalized name: PILOCARPINE 5MG/UNT OPH,CRC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilocarpine 5 mg four times daily
Trial: 21702402
Drug: Pilocarpine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilocarpine (both doses)
Trial: 19318991
Drug: 14-month treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14-month treatment for ADHD
Trial: 17520154
Drug: 1% adenosine-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% adenosine-containing dissolvable film, applied twice daily for three weeks
Trial: 17520154
Drug: 1% adenosine-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% adenosine-containing dissolvable film, applied twice daily for eight weeks
Trial: 12182690
Drug: ER felodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ER felodipine 5 mg once daily for 2 weeks
Trial: 12182690
Drug: ER felodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ER felodipine 10 mg/day for 2 weeks in non-responders
Trial: 12182690
Drug: ER felodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ER felodipine 5 mg and 10 mg/day
Trial: 12182690
Drug: ER felodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ER felodipine 5 to 10 mg/day
Trial: 9838913
Drug: 30-minute drip
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-minute drip infusion of granisetron (40 micrograms/kg with 100 ml saline)
Trial: 9838913
Drug: 30-second injection
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30-second injection of granisetron (40 micrograms/kg with 10 ml saline)
Trial: 7528850
Drug: Ajmaline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ajmaline (1 mg/kg as bolus followed by infusion of 15 micrograms/kg/min)
Trial: 7528850
Drug: Propafenone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone (2 mg/kg, followed by infusion of 30 micrograms/kg/min)
Trial: 24024322
Drug: Xiao Pi‐II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiao Pi‐II (100 mL, t.d.s., ante cibum)
Trial: 24024322
Drug: Mosapride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosapride (5 mg, t.d.s., ante cibum)
Trial: 16611279
Drug: Tenatoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenatoprazole 40 mg fasting at 7.00 AM
Trial: 16611279
Drug: Tenatoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenatoprazole 40 mg fasting at 7.00 PM
Trial: 16611279
Drug: Tenatoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenatoprazole 40 mg fed at 9.30 PM
Trial: 14523040
Drug: anti-IL-5 monoclonal
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: anti-IL-5 monoclonal antibody (mepolizumab)
Trial: 10962766
Drug: 12-session cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-session cognitive behavioral therapy (CBT)
Trial: 10962766
Drug: four‐session motivational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: four‐session motivational enhancement therapy (MET)
Trial: 1653883
Drug: Lisinopril (L)
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril (L) 10, 20, or 40 mg per day
Trial: 1653883
Drug: Captopril (C)
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril (C) 25, 50, or 100 mg per day
Trial: 29767459
Drug: Patiromer 8.4-33.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patiromer 8.4-33.6 g divided twice daily
Trial: 27599871
Drug: Sulcardine sulfate
RxNorm normalized name: SULFATE
DrugBank: Sulfate ion (DB14546)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulcardine sulfate 200 mg
Trial: 27599871
Drug: Sulcardine sulfate
RxNorm normalized name: SULFATE
DrugBank: Sulfate ion (DB14546)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulcardine sulfate 400 mg
Trial: 27599871
Drug: Sulcardine sulfate
RxNorm normalized name: SULFATE
DrugBank: Sulfate ion (DB14546)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulcardine sulfate 800 mg
Trial: 27599871
Drug: Sulcardine sulfate
RxNorm normalized name: SULFATE
DrugBank: Sulfate ion (DB14546)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulcardine sulfate 400 mg (fed)
Trial: 26181091
Drug: 14 pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 pills of study drug (150 microgram levonorgestrel and 30 microgram ethinyl estradiol combined OCPs)
Trial: 24018647
Drug: Intensive glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glucose management strategy aiming at plasma glucose level of 85 to 110 mg/dL using intravenous insulin
Trial: 18937673
Drug: Conventional insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional insulin dosing method (phase B)
Trial: 16144800
Drug: BE-8 infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BE-8 infusion (anti-IL-6 monoclonal antibody)
Trial: 16144800
Drug: Melphalan 220
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan 220 mg/m2 plus dexamethasone with BE-8 infusion
Trial: 16144800
Drug: Melphalan 200
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan 200 mg/m2 and dexamethasone without BE-8 infusion
Trial: 12747286
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) treatment combined with folic acid supplementation (1 mg/d)
Trial: 12747286
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) treatment combined with placebo